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The prevalence of malnutrition in patients with cancer is one of the highest of all patient
groups. Weight loss (WL) is a frequent manifestation of malnutrition in cancer and several
large-scale studies have reported that involuntary WL affects 50–80% of patients with can-
cer, with the degree of WL dependent on tumour site, type and stage of disease. The study of
body composition in oncology using computed tomography has unearthed the importance
of both low muscle mass (sarcopenia) and low muscle attenuation as important prognostic
indications of unfavourable outcomes including poorer tolerance to chemotherapy; signifi-
cant deterioration in performance status and quality of life (QoL), poorer post-operative
outcomes and shortened survival. While often hidden by excess fat and high BMI, muscle
abnormalities are highly prevalent in patients with cancer (ranging from 10 to 90%).
Early screening to identify individuals with sarcopenia and decreased muscle quality
would allow for earlier multimodal interventions to attenuate adverse body compositional
changes. Multimodal therapies (combining nutritional counselling, exercise and anti-inflam-
matory drugs) are currently the focus of randomised trials to examine if this approach can
provide a sufficient stimulus to prevent or slow the cascade of tissue wasting and if this then
impacts on outcomes in a positive manner. This review will focus on the aetiology of mus-
culoskeletal degradation in cancer; the impact of sarcopenia on chemotherapy tolerance,
post-operative complications, QoL and survival; and outline current strategies for attenu-
ation of muscle loss in clinical practice.
Cancer: Cachexia: Survival: Nutrition: Sarcopenia
Involuntary weight loss (WL) is a hallmark feature of
cancer-associated malnutrition, the prevalence of which
has frequently been shown to be one of the highest of all
hospital patient groups(1–3). Several large scale studies over
the past 40 years have reported that involuntary WL affects
50–80% of patients with cancer with the degree of WL
dependent on tumour site, type and stage of disease(4–7).
Malnutrition and involuntary WL at the time of diagno-
sis and deterioration of nutritional status during treatment,
are associated with poor outcomes. A recent large inter-
national cohort of 8160 patients with cancer suggesting
that WL of as little as 2⋅4% predicts survival independent
of disease, site, stage or performance score(6). In addition
to the adverse impact on survival, WL has historically
been associated with severe chemotherapy-related tox-
icity(8–12); and leads to a significant deterioration in a
patients’ performance status, psychological well-being
and overall quality of life (QoL)(13,14).
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Aetiology of malnutrition in cancer
The aetiology of malnutrition in cancer is multifactorial
and includes the effect of nutrition impact symptoms
(NIS) on oral intake, as well as complex metabolic altera-
tions inherent in the disease process(15). The pathophysi-
ology includes derangement of metabolic and hormonal
processes due to inflammatory mediators produced by
the tumour microenvironment, which can impair appe-
tite and promote an inflammatory state associated with
increased energy requirements and anabolic resist-
ance(16,17). Therefore, reduced dietary intake, increased
requirements, altered substrate utilisation and anabolic
resistance, combined with the reduced anabolic stimulus
in the form of exercise, all contribute to malnutrition in
cancer.
Nutrition impact symptoms
As well as abnormal metabolism of nutrients, patients
with cancer often experience a reduction in oral intake
and absorption due to nutrition impact symptoms such
as anorexia, dysgeusia, nausea, constipation diarrhoea,
dysphagia, malabsorption and early satiety. NIS are
caused by both the disease itself and cancer treatments.
Underlying causes range from the mass-effect of tumours
(in the case of pain and dysphagia), as well as more com-
plex, centrally mediated mechanisms such as attenuated
orexigen production (caused by systemic inflammation),
to iatrogenic conditions such as radiation enteritis(18).
NIS are strongly associated with malnutrition, specifi-
cally anorexia and WL(19). Most NIS reported are of
gastrointestinal origin, for example; nausea, vomiting,
constipation, taste and smell changes, dumping syn-
drome and dysphagia. However, pain, fatigue, reduced
functional capacity, financial concerns(20–22) and depres-
sion are also noted by many patients. These varying
symptoms all have a profound impact on QoL(23) and
performance status(24). The impact of NIS on perform-
ance status is of particular concern as reduced activity
levels feed the cycle of cachexia. in that, reduced stimulus
to the muscles can lead to muscle atrophy alongside the
muscle wasting associated with a lack of substrate and
anabolic resistance(25).
Metabolic derangements and increased energy
expenditure
While reduced oral intake is a significant contributor to
WL in cancer, a recent review showed that in studies
where nutritional intake is controlled, WL persists in
many patients(26), suggesting that factors such as hyper-
metabolism and anabolic resistance contribute to cancer-
related WL(27). The presence of cancer in the body causes
a variety of metabolic and endocrine changes (such as
inflammation, anabolic resistance, proteolysis, lipolysis
and futile cycling) induced by the tumour and activated
immune cells. Complex interactions between inflamma-
tion (pro-inflammatory cytokines), neuro-hormonal
changes and potential proteolytic and lipolytic factors
produced by the host and the tumour, fuel WL and
loss of lean mass(15). Hypermetabolism is also thought
to be a significant contributor to energy deficits, with
resultant WL. Depending on the tumour burden, and
the level of anaerobic metabolism, an additional 418–
5858 kJ (100–1400 kcals) can be required daily(28). In
addition, significantly increased production of acute-
phase proteins and cytokines is an energy-intensive pro-
cess(15) and receptors for many cytokines are expressed
in the feeding centres of the hypothalamus, therefore
inflammation-mediated changes in the hypothalamic-
pituitary axis result in illness behaviour(16), including
aberrations in appetite signalling and inhibition of orexi-
gens resulting in poor oral intake(29). Additional factors
such as the browning of adipose tissue(30), changes in
carbohydrate metabolism (Cori cycle upregulation),
changes in fat metabolism (fatty acid cycling), increased
insulin resistance(31) and the demand for amino acids to
drive the inflammatory response, results in increased
muscle proteolysis and reductions in lean mass, which
affects both skeletal muscle and muscular organs, such
as the heart(15). Furthermore, upregulation of the
ubiquitin-proteasome pathway leads to increased muscle
degradation(32).
Increase in sedentary behaviour
A doubly-labelled water study quantifying the physical
activity level (PAL) of healthy adults found that the
PAL of a sedentary adult is 1⋅4–1⋅5(33). Compared to
this, patients with cancer have been shown in a number
of studies to be significantly more inactive that this,
with Moses et al. reporting on twenty-four pancreatic
cancer patients with cachexia, who had a mean PAL of
1⋅24(34) and Gibney et al. who found that lung cancer
patients had a PAL of 1⋅36(35). These values correspond
better with the severely disabled than any healthy, seden-
tary population. Community living spinal cord injury
patients have been demonstrated to have a PAL of
1⋅32(36) and young patients with cerebral palsy a PAL
of 1⋅23(37). These findings attest to the marked impact
of advanced cancer and cachexia on the physical function
and QoL of such patients. Levels of physical activity this
low may exacerbate muscle wasting and it is well under-
stood in any individual that a lack of physical activity
will cause deconditioning and deterioration in muscle
mass.
Weight loss and changes in body composition following a
cancer diagnosis
The end results of the factors discussed earlier is involun-
tary WL which is a hallmark feature cancer-associated
malnutrition. Often referred to as cancer cachexia, it is
now accepted to be a multifactorial syndrome charac-
terised predominantly by the ongoing loss of skeletal
muscle mass (with or without loss of fat mass) that can-
not be fully reversed by conventional nutrition sup-
port(38). Moderate-to-severe WL is present in 30–70 %
of cancer patients(2,4–7,39). In the largest study to-date
of 8160 patients with locally advanced or metastatic dis-
ease, 73 % experienced involuntary WL(6). Table 1 sum-
marises the prevalence of >5% WL (a key component
of the diagnostic criteria of cancer cachexia(38)) according
to tumour site in the scientific literature. WL has
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consistently been shown to be most frequent in patients
with cancers in the upper gut and lung(40–44).
While involuntary WL is reported by the majority of
patients with cancer, a significant proportion remain
overweight or obese by international standards, thus
appearing well-nourished(45). Recent studies have
reported that between 40 and 60% of cancer patients
are overweight or obese (BMI >25 kg/m2) even in the set-
ting of metastatic disease(6,7,46–48). In a recent pooled
analysis of twenty-two randomised trials that included
11 724 patients with cancer, 67 % were shown to be over-
weight or obese at the time of their cancer diagnosis(49).
As a result, many patients with cancer-related malnutri-
tion are diagnosed with malnutrition late in the course
of their disease as nutritional screening instruments
such as the Malnutrition Universal Screening Tool, and
others, are primarily based on BMI and do not identify
these patients as malnourished until they have lost sign-
ificant weight. Neither BMI nor percentage WL can cap-
ture changes in body composition and specifically
changes in muscle mass(45). Muscle loss is the most clin-
ically relevant phenotypic feature of cancer cachexia and
identifying those with muscle loss can become a huge
challenge in overweight and obese patients(39). It is also
important to note that although muscle loss is commonly
associated with cancer, cancer is a disease associated with
ageing, and therefore the aetiology of muscle loss in
patients with cancer can be 2-fold, first resulting from
the age-related decline in muscle mass and second due
to cytokine-mediated degradation of muscle and adipose
depots, hypermetabolism and anorexia associated with
cancer cachexia(15). Distinguishing the exact cause of
muscle loss can be difficult.
Lean mass
Computed tomography is now considered a gold stand-
ard method of body composition assessment and is of
particular convenience in oncology research as these
scans are readily available because they are used as
part of routine medical care. Axial computed tomog-
raphy images at the level of L3 are analysed to determine
muscle mass, muscle radiodensity and adipose tissue
mass (total, subcutaneous and visceral) and excellent
inter-observer reliability has been shown(50). Regression
formulae are available to estimate whole-body compart-
ments using these data. Computed tomography allows
the precise quantification of both muscle and adipose tis-
sue and has led to a large volume of research which has
increased our understanding of the importance of abnor-
mal body composition phenotypes, such as low muscle
mass (sarcopenia), and more recently low muscle attenu-
ation (MA) as important prognostic indicators of
unfavourable outcomes in patients with cancer(6,11,51,52).
Sarcopenia
Sarcopenia is defined by The European Working Group
on Sarcopenia in Older People as ‘a syndrome of progres-
sive and generalised loss of skeletal muscle mass and
strength with a risk of adverse outcomes such as physical
disability, poor quality of life and death’(53,54). While
muscle loss is a normal part of ageing, this syndrome
can also occur in association with disease, such as cancer.
A generally accepted cut-point is skeletal muscle mass 2
standard deviations below that of a healthy, young
population(55).
Sarcopenia is now known to relate to asthenia, fatigue,
impaired physical function, increased chemotherapy tox-
icity, impaired QoL and reduced survival(6,13,45,56).
Recent studies have shown that cancer, and its treatment,
exacerbate muscle loss and that patients continually lose
muscle mass while on treatment(11,57,58). While healthy
adults over the age of 40 years have been shown to lose
muscle at a rate of 1–1⋅4 %/year(59), cancer patients
have been shown to have a 24-fold higher rate of muscle
loss than that observed in healthy ageing adults(57,60). In
studies examining the rate of muscle loss in cancer
patients, rates of 3⋅9%/100 days have been reported in
foregut cancer(57), 3⋅1%/100 days in pancreatic cancer(61)
3⋅3%/100 days in metastatic melanoma(11) and 5⋅2%/100
days in ovarian cancer(58).
Prevalence of cancer cachexia and sarcopenia in
oncology
The prevalence of cancer cachexia and sarcopenia can
vary widely depending on the method of assessment
and diagnostic criteria used(62). From the literature, it
can be estimated that the prevalence of cancer cachexia
(based on WL >5% as per the recent consensus
definition(38)) can vary between 13 and 61% depending
on the tumour site (Table 1), and between 38 and 70 %
of patients are considered to have sarcopenia (based on
three of the most commonly used diagnostic criteria)
(see Fig. 1). The prevalence of sarcopenia is highest in
the lung (median 70 %, range 47–79 %)(63–66) and pancre-
atic cancer (median 56 %, range 44–89%)(41,61,67–73) how-
ever, it is noteworthy that the majority of studies report a
prevalence of above 40% at most other sites in the body.
Our group recently estimated the incidence and preva-
lence of cachexia and sarcopenia in the UK and
Ireland(74). We estimated that across the Republic of
Ireland and UK at least 128 892 cancer patients are
affected by WL >5% annually (34 %) and that there
are 716 124 cancer survivors who have suffered >5%
WL at some point in their disease trajectory.
Furthermore, we estimated that there are at least 133
707 annual cases of cancer patients with sarcopenia (35
%) and 771 589 cancer survivors alive who have been
affected by sarcopenia during their disease trajectory.
Table 1. Prevalence of patients with >5% weight loss according to
primary tumour location in the scientific literature
Primary cancer
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The rates of muscle wasting seen in cancer populations
are of huge public health importance, given that cancer
cachexia and sarcopenia have been reported to be
unequivocally associated with negative clinical outcomes
in patients with cancer including poorer tolerance to
anti-cancer treatment, poorer overall QoL, increased
risk of post-operative complications and poorer overall
survival(6,13,56,62).
Skeletal degradation in cancer treatment
As well as the ongoing loss of muscle mass, several
anti-cancer therapies (both hormonal and non-hormonal)
promote bone loss through direct dysregulation of bone
turnover and indirectly through hypogonadism and nephro-
toxicity. The rate of bone loss from cancer therapy can be
ten times higher than in the general population(75–79) but
is highest in breast and prostate cancer(75) due to commonly
administered therapies such as endocrine therapy (breast
cancer) and androgen deprivation therapy (prostate cancer).
Chemotherapy drugs (cisplatin, doxorubicin, cyclophospha-
mide, ifosfamide, FOLFIRI, carboplatin, methotrexate and
targeted therapies) cause reduced bone volume and radi-
ation therapy, orchiectomy and oophorectomy also result
in bone loss. The onset of bone loss from premature
menopause is sudden (within 6 months of treatment) and
significant (21% decreased density v. age-matched menstru-
ating women(80)). For men with prostate cancer on andro-
gen deprivation therapy loss of bone starts within 6–9
months with annual declines of between 2 and 8%(81–83).
Reduction in bone quality is also further exacerbated by
inactivity. Muscle weakness and exercise intolerance can
persist from months to years after remission(84,85). Excess
bone resorption can lead to fractures and spinal cord
compression(75).
Why malnutrition matters: impact on tolerance to
systemic chemotherapy
Chemotherapy can often be associated with severe tox-
icity that can result in dose delays, dose reductions and
treatment termination, referred to as dose limiting toxici-
ties. Moderate to severe toxicities can lead to interrup-
tion, deferral or even cessation of treatment. Severe
toxic events can result in hospitalisations and can even
be life-threatening. Recent evidence suggest that variabil-
ity in body composition of cancer patients may be a
source of disparities in the metabolism of cytotoxic
agents resulting in increased toxicity(86–88).
To date, in excess of forty studies have examined the
relationship between low lean mass (sarcopenia) and
the prevalence of dose limiting toxicity in patients with
cancer (we have previously reviewed these(89)). The rela-
tionship between sarcopenia and increased chemother-
apy toxicity has been reported in both early and
late-stage disease, at almost all cancer sites and with
many modalities of cytotoxic agents (cytotoxic single
agents, regimens, targeted agents and immunother-
apies)(90–93). Although the relationship between low
lean mass and poorer tolerance to treatment has been
observed in the majority of studies, a few smaller studies
have reported no association(60,71,94–99).
Fig. 1. Prevalence of sarcopenia in patients with cancer according to the primary tumour location in the literature (all
stages).(63–68,136,41,61,69–73,111,180,256–260,90,94,261–264,12,113,265–270,95,271–275,52,60,149,150,276,277,185,260,278–280,86–88,281,282,283–
287,91,288–293,11,47,57,58,92,162,164,268,294,295,7,93,96,100,165,296–299).
Prevalence of sarcopenia defined using three of the most common definitions for defining low muscle mass is
displayed in Table 1. These definitions are as follows; Prado et al.(92): Skeletal muscle index (SMI)<52⋅4 cm2/m2 in men
and <38⋅5 cm2/m2 in women; Martin et al.(47): SMI <43⋅0 cm2/m2 in men with a BMI <25 kg/m2 and <53⋅0 cm2/m2 in
men with a BMI >25 kg/m2 and SMI <41⋅0 cm2/m2 in women; Baumgartner et al.(55) converted dual-energy X-ray
absorptiometry cut points by Mourtzakis et al.(300) as SMI <55 4 cm2/m2 in men and <38⋅9 cm2/m2 in women.






















Downloaded from https://www.cambridge.org/core. University College Cork, on 02 Dec 2021 at 15:42:26, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
Low lean mass can lead to increased toxic side effects
to chemotherapy through alterations in the distribution,
metabolism and clearance of chemotherapy drugs(100).
The widespread use of body surface area (BSA), relying
on height and weight alone(101), in dosing chemotherapy
drugs presents a problem as there are large discrepancies
in muscle mass between people of the same BSA, result-
ing in potential under or over-dosing when calculations
are based on a simple BSA formula(102–104). A
4–10-fold variation in drug clearance is possible in indi-
viduals with a similar BSA and there is concern that
this approach to dosing is invalid(105,106). Bodyweight
comprises two major components (lean and fat mass)
then these are the two major sites of distribution of
hydrophilic and lipophilic drugs(107,108). Therefore, vari-
ability in individual lean mass or fat mass may lead to
changes in the volume of distribution of drugs and there-
fore adversely affect the tolerance of cytotoxic drugs(62).
In sarcopenic obesity, tolerance is further compromised
in individuals where the combination of excessive fat
mass and low lean mass may significantly impact the tol-
erance of hydrophilic drugs by resulting in a dispropor-
tionally small volume of drug distribution in relation to
their body weight or BSA(100,107). Variations in lean
and fat mass can therefore lead to considerable variation
in the milligram of chemotherapy drug per kilogram lean
mass with higher doses per kilogram lean mass shown to
be associated with more frequent and severe toxic side
effects(107,109,110). This hypothesis is supported by phar-
macokinetic data, with sarcopenic patients experiencing
higher plasma concentrations of antineoplastic drugs
and experiencing more toxicity(111,112). For lipophilic
drugs such as doxorubicin or trabectedin, individuals
with a low-fat mass may also present with toxicity due
to a reduced volume of distribution(108).
It is also important to note that sarcopenic patients are
excessively fragile and highly susceptible to acute medical
events that exacerbate chemotherapy-related toxicity(113).
In addition, for those patients with systemic inflamma-
tion, this has been shown to decrease liver cytochrome
activities and drug clearance and may modify drug
exposure. Low concentrations of circulation plasma pro-
teins (e.g. albumin), which is commonly seen in those
with malnutrition or systemic inflammation (or both)
may also affect the distribution of highly protein-bound
drugs such as vandetanib, sorafenib and epirubi-
cin(108,111,112). As imaging techniques in body compos-
ition become more widely used, this may represent an
opportunity for a more personalised approach to chemo-
therapy dosing.
Why malnutrition matters: impact on performance status
and quality of life
The adverse impact of WL on QoL has long been recog-
nised in patients with cancer and WL has been associated
with deterioration in patients’ performance status and
psychosocial well-being(40,114,115). In a recent systematic
review examining the impact of WL and QoL, a negative
relationship between %WL and QoL was reported in
twenty-three of twenty-seven studies included in the
analysis(13). However, the mode by which WL exerts its
influence on QoL is not fully understood but may relate
to muscle atrophy associated with cachexia and WL lead-
ing to fatigue or reduced functional capacity(116). The
negative impact on QoL is unsurprising, considering
cancer-related malnutrition is a major cause of
fatigue(117,118), reduced functional ability(116) and a
source of emotional distress(117,119). Our group recently
reported on a cohort of 1027 patients with advanced can-
cer and showed that WL >10% was associated with
poorer QoL in almost all functional and symptom
domains(14). In particular, WL in excess of 10 % in the
preceding 3 months was independently associated with
poorer physical function, fatigue and appetite loss and
overall poorer QoL summary scores.
While there is no doubt that WL impacts negatively on
QoL, inconsistent reports on the relationship between
muscle parameters and QoL have been published in the
literature(97,120–122). Parsons and colleagues reported no
significant associations between low Skeletal muscle
index and symptom burden or functional life domains
assessed by the MD Anderson Symptom Inventory, in
a cohort of 104 patients with advanced cancer(97).
However, in a study of 734 advanced lung cancer
patients, low Skeletal muscle index was non-linearly
associated with lower global QoL, physical function
and role function, and associated with more symptoms
(fatigue and pain), while low MA was associated with
poor physical function and more dyspnoea(122).
Sarcopenia has also been associated with greater depres-
sion symptoms and more fatigue in patients with
advanced cancer(120,121). It may be that low Skeletal mus-
cle index, at a single time point, is not reflective of a
dynamic measure of loss and may be influenced by a
patient’s intrinsic level of muscularity. Perhaps the loss
of muscle over time may better reflect poor QoL and fur-
ther research is needed in this area.
The mode by which WL exerts its influence on QoL is
not fully understood but may relate to muscle atrophy
associated with cachexia and WL leading to fatigue or
reduced functional capacity. Recent work has suggested
that the complex interplay between metabolic disruption
and pro-inflammatory cytokines (i.e. IL-6, IL-8 and
TNF-α) in cancer cachexia often leads to physical, bio-
chemical and nutritional deterioration which subse-
quently leads to poor QoL(123). It is thought that the
systemic inflammatory response has a direct role in the
development of cancer-associated symptom clusters,
including pain, fatigue, mood, anorexia and physical
function(124). Systemic inflammation and loss of lean
mass are also thought to drive cancer-related fatigue,
which is thought to affect up to 80 % of cancer
patients(125) both during and after treatment cessa-
tion(125–128). Severe and persistent fatigue, along with
muscle mass wasting has been shown to inhibit QoL by
considerably reducing functional capacity to fully partici-
pate in daily living tasks(125). Individual proinflammatory
cytokines have been associated with clinical symptoms,
e.g., IL-6 and C-reactive protein with anorexia(129),
IL-1ra with fatigue(129) and IL-6 with major depres-
sion(130,131). Our group recently reported that systemic






















Downloaded from https://www.cambridge.org/core. University College Cork, on 02 Dec 2021 at 15:42:26, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
inflammation has a negative impact on QoL that is inde-
pendent of Eastern Cooperative Oncology Group per-
formance status(14) which is consistent with previous
reports indicating that the systemic inflammatory
response is associated with poorer QoL, even in those
with a good performance score(132).
Importantly, interventions aimed at targeting nutri-
tional status and attenuating weight have proven success-
ful in improving aspects QoL in patients with cancer(133).
In addition, novel cachexia treatments, such as
Anamorelin, an oral ghrelin-receptor agonist with appe-
tite enhancing and anabolic activity have shown a
favourable clinical response in alleviating anorexia-
cachexia symptoms(134). Research is warranted to deter-
mine if attenuating the systemic inflammatory response
is capable of producing clinically relevant improvements
in symptoms that may represent a new therapeutic
approach to symptom management in patients with
advanced cancer.
Impact on survival
The impact of sarcopenia on survival in cancer has been
extensively studied over the past decade. Most studies
report a significant decrease in overall survival in patients
with sarcopenia compared with those without sarcope-
nia, irrespective of the primary cancer site and stage
(see Fig. 2). Figure 1 displays a forest plot depicting
the summary results of meta-analyses examining the
role of sarcopenia in survival in cancer. To-date sarcope-
nia (diagnosed by computed tomography) has been
shown to be independently associated with poorer sur-
vival in all those sites included in the meta-analysis in
Fig. 2 as well as in head and neck(135–140), prostate can-
cer(141), cholangiocarcinoma(142–146), lymphoma(147–151)
and leukaemia(152). In a recent systematic review and
meta-analysis of thirty-eight studies that included 7843
patients with solid tumours, low muscle cross-sectional
area was observed in 27⋅7% of patients with cancer
and associated with poorer overall survival (hazard
ratio (HR) 1⋅44, 95 % CI 1⋅32, 1⋅56), cancer-specific sur-
vival (HR 1⋅93, 95 % CI 1⋅38, 2⋅70), as well as disease-
free survival (HR 1⋅16, 95 % CI 1⋅00, 1⋅30) but not
with progression-free survival (HR 1⋅54, 95 % CI 0⋅90,
2⋅64)(153). This meta-analysis demonstrated that the
adverse effects of low lean mass on overall survival
were similar in both metastatic (HR 1⋅37, 95 % CI
1⋅21, 1⋅56) and non-metastatic disease (HR 1⋅54, 95 %
CI 1⋅31, 1⋅79), and this relationship was observed across
different primary tumour sites. Recently, in two of the
largest observational cohort studies to date, Caan and
colleagues(154,155) demonstrated the prognostic value of
low muscle mass in non-metastatic breast (n 3241) and
colorectal cancer (n 3262). Low lean mass was present
in 34 and 42 % of patients, respectively, and was inde-
pendently associated with a 27–41 % higher risk of over-
all mortality (colon: HR 1⋅24, (95 % CI 1⋅09, 1⋅48);
Breast: HR 1⋅41 (95 % CI 1⋅18, 1⋅69)](154,155).
In addition to low muscle area (sarcopenia), low MA
(density; indicative of fatty infiltration of muscle tissue)
is also associated with poorer survival in a variety of
tumours including non-small cell lung cancer(156), colo-
rectal(157–159), endometrial(160), renal(161), ovarian can-
cer(162) and melanoma(163). Importantly, in some cases,
low MA appears to superior in predicting mortality com-
pared with low lean mass alone(156,164–167). However, it
has also been demonstrated that the risk of mortality
associated with low lean mass and low MA can be inde-
pendent of each other(146,168,169).
Lastly, the combination of sarcopenia and obesity has
been shown to have particularly poor clinical outcomes.
This may be related to the combined negative effects of
both conditions or may be related to poor detection of
sarcopenia in a cohort whose muscle loss is masked by
excess adiposity. Sarcopenic obesity specifically has
been associated with poorer survival in a number of
cohorts(92,170).
Why malnutrition matters: impact of muscle loss during
treatment and survival
Notwithstanding the impact of sarcopenia on survival,
several studies have emphasised that patients continually
lose muscle mass while on treatment and that this is asso-
ciated with an increased risk of mortality in a number of
cancers. Patients with advanced pancreatic cancer (n 97)
who experienced the early loss of skeletal muscle (>10 %
within 3 months of diagnosis) were at increased risk of
poorer overall survival and progression-free survival
compared to patients who did not experience muscle
loss to the same degree (HR 2⋅16 (95 % CI 1⋅23, 3⋅78),
P= 0⋅007 and HR 2⋅31 (95 % CI 1⋅30, 4⋅09),
P= 0⋅004)(171). In patients with surgically resected stage
I-III colorectal cancer (n 1924), those who experienced
the largest decrease in muscle mass (≥2 standard devia-
tions or the equivalent to ≥11⋅4% loss) and the largest
decline in mean MA (≥2 SD; ≥20⋅2% loss) from baseline
were at a significantly increased risk of mortality (HR
2⋅15, 95 % CI 1⋅59, 2⋅92), P < 0⋅001 and HR 1⋅61 95%
CI 1⋅20, 2⋅15, P = 0⋅002, respectively), and these findings
were independent of changes in body mass or other body
composition parameters(158). To date, losses in muscle
have been shown to be prognostic of reduced survival
in pancreatic(72,171), oesophageal(172), gastric(173),
lung(174), colorectal(60,175,176), ovarian(58), melanoma(11)
and foregut cancers(57).
Why malnutrition matters: impact on surgical outcomes
In cancer patients undergoing surgery, length of stay and
post-operative complications are important indicators of
surgical morbidity. Sarcopenia has been independently
associated with adverse post-operative outcomes including
infections, complications, the longer length of hospital
stay and risk of readmission following gastrectomy(177,178),
pancreatectomy(179), oesophagectomy(180,181), cystecto-
my(182)pneumonectomy(183,184) and colectomy(185–187).
Even in those without complications, length of stay has
been shown to be significantly longer in patients with mus-
cle abnormalities(188–190).
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Potential therapies for malnutrition in cancer
Despite much evidence that impaired nutritional status is
associated with poor outcomes, the evidence-base regard-
ing the optimal management of malnutrition in cancer
and the ability to improve nutritional status to improve
clinical outcomes is lacking(191). While the treatment of
malignancy is the primary method of reversing the meta-
bolic environment which perpetuates cachexia, support-
ive care is required while this process ensues. In the
early stages of cancer cachexia, malnutrition may be
reversible; however, in later stages of the disease, it has
been difficult to attain significant improvements in nutri-
tional status, although it has been suggested that with the
right combination of therapies, even patients with
advanced disease may exhibit anabolic potential.
Dietetic management
Nutritional interventions have been a mainstay of cachexia
management to date. Nutritional counselling, consisting of
dietary advice and ongoing education is the first line for
treatment of malnutrition(191). While a food-first approach
to a high-protein, high-energy diet is recommended, nutri-
tion support, starting with the use of oral nutritional sup-
plements is frequently required to augment volitional
intake where appetite is limited. Furthermore, artificial
nutrition in the form of enteral or parenteral nutrition
may be required due to dysphagia, obstruction of the
gastrointestinal tract or severe malabsorption(192). The
European Society for Clinical Nutrition and Metabolism
(ESPEN) released consensus guidelines in 2017 for the
nutritional management of cancer patients(191). Despite
limited evidence that nutritional interventions improve
clinical outcomes, ESPEN strongly recommends, with
moderate evidence, that nutritional interventions be
employed in those at risk of malnutrition, aiming to
increase oral intake, by providing dietary advice, manage-
ment of metabolic derangements and nutrition impact
symptoms, as well as the provision of oral nutritional sup-
plementation where needed. ESPEN recommend that
patients’ total energy expenditure be assumed as 105–
126 kJ/kg (25–30 kcal/kg) body weight daily, unless the dir-
ect measurement is available. Given that cancer patients
can be hypo-, normo- or hypermetabolic, and displaying
varying levels of anabolic resistance, it seems reasonable,
in the absence of direct measurements, to take a pragmatic
approach, and adjust requirements according to clinical
response to the initial estimation.
Apart from energy requirements, meeting protein
needs is also a priority in order to maintain lean mass
Fig. 2. (Colour online) Forest Plot depicting summary results of meta-analyses examining the role of
sarcopenia in survival in cancer. Asterisks denote studies which did not confirm the inclusion of multivariate
data in the meta-analysis(153,301–304,305–310,170,311–315).
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and support recovery throughout the cancer journey.
ESPEN recommend 1–1⋅5 g protein/kg body weight in
cancer patients but suggest that research is necessary to
determine whether a higher level such as 2 g/kg may be
beneficial(191). PRIMe (ClinicalTrials.gov ID: NCT
02788955) is a feasibility study (n 40) comparing isoener-
getic diets in colorectal cancer with either 1 g protein/kg
body weight or 2 g protein/kg body weight and assessing
the impact of the varying protein intakes on muscle mass
and physical functioning.
A number of individual studies have demonstrated
positive impacts of nutritional interventions on relevant
outcomes. A number of studies have demonstrated that
dietitian-led clinics and intensive dietary counselling
can reduce nutrition-related admissions(193,194) and
reduce the length of stay(195). Improved energy and pro-
tein intake(196,197) and weight(198,199) were noted in some
studies and these increases led to improved QoL, func-
tioning and nutritional status(200).
A recent national survey led by our research group in
Ireland examined the attitudes and experiences of patients
with cancer (n 1085) to nutrition(201). Overall 45%
reported problems with diet and eating, 44% had experi-
enced involuntary WL (mean loss reported 10⋅4 kg, range
1–44 kg) and 52% reported they had noticed muscle loss.
The majority (67%) wanted more information on diet
with 51% reported they were concerned about their nutri-
tional status and confused by what to eat. Worryingly one
in three with involuntary WL had not been able to access
a registered dietitian (RD) for individual advice. Despite
ESPEN recommendation that all patients receive routine
nutritional screening and intervention early in the course
of malnutrition(191), access to RD for cancer patients is
poor. For example, evidence-based guidelines from
Australia recommend that all patients receiving radio-
therapy to the gastrointestinal tract or head and neck
area are routinely referred to dietitians(202), however, a
service provision audit in the UK found that only 69%
of head and neck cancer patients see a dietitian, with
those having oral tumours the most likely to be
referred(203). Generally speaking, there is a lack of dieti-
tians providing care to those affected by cancer. In
Ireland, as of 2016, there were thirty-six RD working in
cancer care, of which only five are practising outside the
capital city of Dublin, which provides only one dietitian
to every 1389 active cancer patients(204). This represents
all dietitians who cover oncology as part of their role
and does not constitute the number of dedicated oncology
dietitians. In the USA, there are approximately 1⋅7 full-
time equivalent dietitians per outpatient cancer centre,
corresponding to 1 RD to 1202 patients(205). In Ontario,
Canada, there are few dietitians practising in oncology
and palliative care, with 1⋅1–1⋅6 full-time equivalent full-
time equivalent RD per 100 inpatient beds and 0⋅2–1⋅4
full-time equivalent/100 patients in the outpatient set-
ting(206). There is also a lack of specialist dietitians in
oncology, with only 370 board-certified oncology special-
ist dietitians in the USA(207).
When malnourished patients are seen by dietitians the
mainstay dietary treatment, particularly for those with
poor appetite is a ‘little and often, high protein high
energy diet’. This diet constitutes a food-first approach
which involves counselling patients and their carers on
foods that are naturally high in protein and energy and
providing meal and snack options to achieve this. Our
group has developed several cookbooks to bring this
advice to life over the past number of years and these
are available as free downloadable e-books at www.
breakthroughcancerresearch.ie/books. These resources
are written in lay language and provide simple high pro-
tein high energy meal options. For some patients with
continued problems with poor appetite and early satiety,
oral nutritional supplements and/or enteral feeding will
be necessary to support their nutritional status during
cancer treatment.
Systemic inflammation
As observed by Sir David Cuthbertson in 1942(208) in ref-
erence to the post-shock metabolic response ‘it is doubt-
ful whether, during the early catabolic phase, any dietary
measure can effectively suppress the catabolic destruction
of protein’. One could argue the same is true for cancer
where systemic inflammation is present. Systemic inflam-
mation is present in 30–50 % of advanced cancer popula-
tions(209) and is an independent factor reducing
survival(210). Over the years several pharmaceutical and
dietary factors have been examined to reduce inflamma-
tion including corticosteroids, non-steroidal inflamma-
tory drugs, statins and n-3 fatty acids. Corticosteriods
appear to increase appetite and QoL for a limited period
of time but the optimal dose, duration or timing of inter-
vention is not clear. There is good evidence that non-
steroidal anti-inflammatory drugs can lead to increases
in body weight in cachexia and a plausible mechanism
is the attenuation of cachexia-related inflammation and
subsequent modulation of the anabolic resistance asso-
ciated with cancer cachexia. However, non-steroidal anti-
inflammatory drugs do have some risks, such as gastro-
intestinal bleeding, and so further evidence is needed to
prove efficacy and safety in cancer cachexia manage-
ment(211). n-3 Fatty acids have been associated with
weight stabilisation(212,213), improved QoL(214,215) and
increased chemo-sensitivity(216) in some studies.
Physical activity
Physical activity and more specifically, structured exer-
cise, has been suggested as part of the management of
cancer cachexia(217). Exercise has been shown to be safe
in individuals living with and beyond cancer(218) and
can promote QoL in patients on active treatment(219)
and during the survivorship period(220). Moreover, the
specific QoL domains impacted by exercise are those
which are commonly impaired in cancer cachexia (phys-
ical functioning, role functioning, fatigue and body
image/self-esteem)(219,220). Of note, it has been shown
that the most QoL benefit is gained from supervised exer-
cise programmes(221) and that those patients with the
lowest baselines experience the most improvement in
fatigue, QoL, aerobic fitness and physical function, indi-
cating that the patients who are most inactive could
benefit from any increase in exercise(222).
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Based on the current evidence, the American College
of Sports Medicine position is that exercise is safe and
beneficial for cancer patients and their guidelines provide
evidence-based recommendations in terms of safety mea-
sures, and exercise prescription specifics across many
tumour types, with a focus on the prescription of physical
activity using the frequency, intensity, time, type frame-
work. The recommended target to achieve the documen-
ted benefits of exercise programmes in cancer is ≥30 min
moderate-intensity aerobic exercise ≥3 times per week
for at least 8–12 weeks and resistance training ≥2 times
per week (≥2 sets of eight–fifteen repetitions ≥60%
one-repetition maximum)(223,224). Likewise, the Clinical
Oncology Society of Australia has a position statement,
as of 2018, which states that all members of the multidis-
ciplinary team should promote physical activity amongst
cancer patients and that patients should be encouraged to
return to normal levels of activity as soon as possible
after diagnosis and that they should aim for ≥150min
moderate-intensity or 75 min vigorous-intensity aerobic
exercise per week and 2–3 sessions of resistance exercise
per week (moderate to vigorous-intensity exercises target-
ing the major muscle groups)(225).
Multimodal approaches
When the multifactorial nature of malnutrition in cancer
is considered, it seems reasonable that a multimodal
approach to treatment may fare better than a unimodal
approach. By targeting multiple aetiologies, there is
some evidence that multimodal therapies may have a bet-
ter chance of attenuating the progression of cachexia(226).
Multimodal management of cancer cachexia should
incorporate general interventions such as nutrition coun-
selling, symptom management and exercise as well as
focused interventions that address specific aetiological
components of the cancer cachexia syndrome, such as
fish oil or non-steroidal anti-inflammatory drug to
address increased inflammation or corticosteroids to
improve appetite(227).
Early intervention is of the utmost importance as
refractory cachexia remains a challenge, still considered
irreversible and associated with a terminal prognosis(38).
The European School of Oncology Task Force’s official
position is that research should focus on the identification
and management of cachexia early in the disease course
when it is amenable to treatment(123). Furthermore, it
has been suggested that a ‘parallel pathway’ approach
should be adopted to ensure that cachexia is managed
alongside cancer itself, recognising their inherent connec-
tion and avoiding the sentiment that cachexia is an inev-
itable endpoint associated with advanced disease, but
rather focusing on optimising clinical outcomes by pre-
venting the development of malnutrition(228).
A systematic review by Hall et al. showed that the cur-
rent literature base for combined nutrition and exercise
programmes in advanced cancer is lacking in strong evi-
dence. While studies to date have shown variable
improvements in QoL, overall function, fatigue, endur-
ance/strength, depression and nutritional status, the
results are inconsistent across studies and they are often
underpowered(229). The strongest evidence in favour of
these trials is only of moderate quality and it suggests
that physical endurance and strength, as well as mood,
can be improved by these interventions. Further well-
designed studies are needed in order to verify the utility
of multimodal approaches.
MENAC, a large multi-centre phase III trial
(A randomised, open-label trial of amultimodal intervention
(exercise, nutrition and anti-inflammatory medication) plus
standard care v. standard care alone to prevent/attenuate
cachexia in advanced cancer patients undergoing chemother-
apy) is currently underway (ClinicalTrials.gov ID:
NCT02330926)(230). Identification of a successful cachexia
treatment would mark significant progress in the field of
oncology nutrition, and given the impact of nutrition of sur-
vival and tolerance to treatment, the oncology field as a
whole.
Conclusions
WL and abnormalities of body composition are common
across all cancer sites and stages and the aetiology of
malnutrition in cancer is multifactorial and complex. It
is associated with poorer QoL as well as increased mor-
bidity and mortality and is often considered an inevitable
part of the cancer trajectory. Irrespective of baseline
BMI, muscle and fat wasting are associated with poorer
outcomes; however, simple screening tools using weight
and BMI alone miss a large proportion of patients with
altered body composition who are at risk nutritionally
and therefore, techniques to adequately identify patients
at risk of malnutrition must be developed and widely
implemented in order to facilitate early-intervention
and a parallel pathway.
Despite the widespread fatalism with respect to cancer
cachexia, patients do retain anabolic potential and
although nutritional interventions, to date, have not
been shown to increase survival, it may be that these
interventions have not been successful in addressing the
malnutrition as a primary outcome and thus, the
benefit of survival has not been borne out. With more
successful therapies, including multimodal and interdis-
ciplinary approaches, it may be that nutritional interven-
tions can improve not only QoL but also the length of
life. Management of cancer-related malnutrition must
focus on early-intervention with multimodal approaches
in order to tackle the multifactorial nature of cachexia
pathophysiology.
Further research into the pathogenesis and conse-
quences of cancer-related malnutrition may lead to a bet-
ter understanding of potential targets for treatment.
However, while a number of promising therapies for
cachexia are under investigation, the field lacks currently
licensed treatments and so interventional research must
be prioritised in order to provide an evidence base for
the treatment of the condition which is now well docu-
mented as causing poor outcomes.
In conclusion, prompt identification of patients with
cancer-related malnutrition must be optimised and devel-
opment of an effective, evidence-based treatment strategy
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is of the utmost importance as it stands to improve lon-
gevity and QoL for cancer survivors.
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